% | $
Quotes you view appear here for quick access.

Affymax, Inc. Message Board

  • shabamoon shabamoon Apr 10, 2013 8:00 PM Flag

    $$$$$ Affymax WINS: $180 million + 13-17% of NET US SALES + 13-24% of NET SALES ex-US

    "As a result of the Amendment, Takeda assumes full responsibility for OMONTYS, including the ongoing recall and investigation of OMONTYS as well as any subsequent decisions as to whether the product may be subject to re-introduction if Takeda is able to complete the investigation and address the safety concerns to the satisfaction of the FDA. If Takeda decides to re-introduce OMONTYS, all of which is highly uncertain, the Company is eligible to receive royalties and (i) potential commercial milestone payments totaling up to $180 million of which $10 million is payable upon the first commercial sale after re-introduction of OMONTYS in the U.S., of which a $10 million and another $10 million relates to U.S. sales-based milestones, and of which $150 million relates to sales-based milestones in amounts as previously disclosed outside of the U.S. but now including Japan as a result of the Amendment and (ii) a potential development milestone payment of $5 million payable either upon regulatory approval in the E.U. or Japan. The royalties are tiered in the range of 13-17% with respect to net sales in the U.S. and in the range of 13-24% depending on the level of net sales by Takeda worldwide ex- U.S. "

    In addition all investigation responsibilities and costs plus future production and distribution and marketing of Omontys goes solely to Takeda.

    FOLKS FOLKS FOLKS....Don't be fooled by AH stock price. The agreement gives Affymax the best of both world. I think if not for manipulation this stock would open at $3 + tomorrow morning and be back at $15 within months of Omontys is back in the market.

    And back Omontys will; I think this is quite obvious now.

    Sentiment: Strong Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies
0.07990.0000(0.00%)Oct 26 1:52 PMEDT